Here's Why Mirum Pharmaceuticals Rocketed 240% in December
Shares of Mirum Pharmaceuticals (NASDAQ: MIRM), a clinical-stage biopharmaceutical company, soared 240.1% in December, according to data from S&P Global Market Intelligence. Investors were responding to important steps forward the company took, including with its experimental treatment for children with rare liver diseases, maralixibat.
Maralixibat is the only clinical-stage new drug candidate in Mirum Pharmaceuticals' pipeline. The stock surged last month because the company told investors the FDA is willing to review a rolling submission of a new drug application for maralixibat.
Image source: Getty Images.
Source Fool.com